ArticleNucleic acids research2000
Antisense delivery using protamine-oligonucleotide particles.
Article in Nucleic acids research, 2000. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 1 synthesis or guideline pooled it, 97 citations in OpenAlex.
- Synergistic innovations of nanomedicine in lymphoma treatment: a systematic review.Journal of translational medicine · 2025Pooled it
- Nanotechnology and CRISPR/Cas-Mediated Gene Therapy Strategies: Potential Role for Treating Genetic Disorders.Molecular biotechnology · 2025Review
- A Review of Protein- and Peptide-Based Chemical Conjugates: Past, Present, and Future.Pharmaceutics · 2023Review
- Modified Stability of microRNA-Loaded Nanoparticles.Pharmaceutics · 2022Article
- Cooperating minimalist nanovaccine with PD-1 blockade for effective and feasible cancer immunotherapy.Journal of advanced research · 2022Article
- Recent Advances in the Delivery Carriers and Chemical Conjugation Strategies for Nucleic Acid Drugs.Cancers · 2021Review
- Emerging Applications of Nanotechnology in Healthcare Systems: Grand Challenges and Perspectives.Pharmaceuticals (Basel, Switzerland) · 2021Review
- Use of Protamine in Nanopharmaceuticals-A Review.Nanomaterials (Basel, Switzerland) · 2021Review
- Encapsulating TGF-β1 Inhibitory Peptides P17 and P144 as a Promising Strategy to Facilitate Their Dissolution and to Improve Their Functionalization.Pharmaceutics · 2020Article
- Immune-Mediated Inflammation in Vulnerable Atherosclerotic Plaques.Molecules (Basel, Switzerland) · 2019Review
- Manufacturing of a Secretoneurin Drug Delivery System with Self-Assembled Protamine Nanoparticles by Titration.PloS one · 2016Article
- Recent Advances in Targeted, Self-Assembling Nanoparticles to Address Vascular Damage Due to Atherosclerosis.Advanced healthcare materials · 2015Review
- Lipoprotein-Related and Apolipoprotein-Mediated Delivery Systems for Drug Targeting and Imaging.Current medicinal chemistry · 2015Review
- Oncomodulin/truncated protamine-mediated Nogo-66 receptor small interference RNA delivery promotes axon regeneration in retinal ganglion cells.Molecules and cells · 2014Article
- Mannosylated chitosan nanoparticles for delivery of antisense oligonucleotides for macrophage targeting.BioMed research international · 2014Article
- Interleukin 10-coated nanoparticle systems compared for molecular imaging of atherosclerotic lesions.International journal of nanomedicine · 2014Article
- Next generation delivery system for proteins and genes of therapeutic purpose: why and how?BioMed research international · 2014Review
- In vivo delivery of cell-permeable antisense hypoxia-inducible factor 1α oligonucleotide to adipose tissue reduces adiposity in obese mice.Journal of controlled release : official journal of the Controlled Release Society · 2012Article
- A covalently stabilized lipid-polycation-DNA (sLPD) vector for antisense oligonucleotide delivery.Molecular pharmaceutics · 2011Article
- New tumor-targeted nanosized delivery carrier for oligonucleotides: characteristics in vitro and in vivo.International journal of nanomedicine · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Protamine, a polycationic peptide (mol. wt 4000-4500), was evaluated as a potential penetration enhancer for phosphodiester antisense oligonucleotides (ODNs). Unique complexes in the form of nanoparticles were spontaneously formed, which we call 'proticles'. The stability of the particles and the ODNs bound into the proticles was examined in foetal calf serum and cell culture medium. FITC-labelled ODNs bound to protamine showed an increased cellular uptake into human histiocytic lymphoma U 937 cells compared to free ODNs. Proticles significantly decreased cellular growth in a cell proliferation assay using ODNs against the c- myc proto-oncogene.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.